Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128080 | 0.77 | IDO1 (0.52) | MAOBAPPMAOARAB9ASMN1; SMN2 | |
| SCHEMBL8145077 | 0.77 | IDO1 (0.47) | MAOBALDH1A1GFERCYP3A4TSHR | |
| SCHEMBL4301091 | 0.77 | IDO1 (0.47) | MAOBALDH1A1GFERCYP3A4TSHR | |
| SCHEMBL31541669 | 0.77 | LTA4H (0.39) | ALDH1A1TSHRIDO1AGXTMEN1 | |
| SCHEMBL1705503 | 0.76 | TSHR (0.52) | ALDH1A1TSHRL3MBTL1IDO1AGXT | |
| SCHEMBL29143218 | 0.74 | IDO1 (0.55) | TSHRGAARAB9AIDO1AGXT | |
| SCHEMBL4314773 | 0.74 | TSHR (0.41) | MAOBALDH1A1GFERCYP3A4TSHR | |
| SCHEMBL38665417 | 0.74 | CA2 (0.61) | MAPTSMN1; SMN2 | |
| SCHEMBL31541632 | 0.74 | CA2 (0.48) | KMT2A | |
| SCHEMBL31508075 | 0.74 | GABRP (0.44) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160952-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200709-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7902232-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7803832-B2 | N-(1-arylpyrazol-4L)sulfonamides and their use as parasiticides | PFIZER INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7687533-B2 | N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20100075956-A1 | N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES | PFIZER INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20080261940-A1 | N-(1-Arylpyrazol-4L) Sulfonamides and their Use as Parasiticides | ZOETIS LLC | 2008-10-23 | — | — | US | disclosed |
| US-7435753-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2008-10-14 | — | — | US | disclosed |
| EP-1901608-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| EP-1735284-A1 | N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES | Pfizer Limited (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006134466-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| EP-1705989-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| US-20060014802-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2006-01-19 | — | — | US | disclosed |
| WO-2005090313-A1 | N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| US-20050148649-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2005-07-07 | — | — | US | disclosed |
| WO-2005060749-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | MAOB 795/4885ALDH1A1 963/4885GFER 2267/4885 |
| US-20100075956-A1 | N-(1-ARYLPYRAZOL-4L)SULFONAMIDES AND THEIR USE AS PARASITICIDES | ARSA, STS, SULT1E1 | MAOB 3368/4885ALDH1A1 421/4885GFER 1009/4885 |
| US-20050148649-A1 | Substituted arylpyrazoles | CYP3A4, CYP4B1, CYP1B1 | MAOB 246/4885ALDH1A1 346/4885GFER 1722/4885 |
| US-20060014802-A1 | Substituted arylpyrazoles | CYP4X1, ARG1, CYP2C9 | MAOB 736/4885ALDH1A1 1045/4885GFER 2083/4885 |
| US-20080261940-A1 | N-(1-Arylpyrazol-4L) Sulfonamides and their Use as Parasiticides | ARSA, STS, SULT1E1 | MAOB 3368/4885ALDH1A1 421/4885GFER 1009/4885 |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A43, CYP3A4, CYP4X1 | MAOB 803/4885ALDH1A1 358/4885GFER 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.